Multicenter, placebo‐controlled, double‐blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

Shunichi Sugawara(Sendai Kousei Hospital), Tomohide Tamura(St. Luke's International Hospital), Tomoya Fukui(Wakayama Medical University), Kozo Yoshimori(Japan Anti Tuberculosis Association), Akira Iwashima, Koichi Minato, Naoki Inui(Hamamatsu University School of Medicine), Yuichiro Takeda(National Center for Global Health and Medicine), Kaoru Kubota(Nippon Medical School Hospital), Toru Kumagai(University of Pennsylvania), Toshiaki Saeki(Saitama Medical University), Masahiro Morise(Nagoya University), Masashi Kanehara(Miyoshi Kasei (Japan))
Cancer
August 5, 2019
10.1002/cncr.32429
Cited by 16

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k